Last updated: April 4, 2026
Case Overview
Galderma Laboratories LP filed suit against Taro Pharmaceuticals USA Inc. on March 3, 2010, asserting patent infringement related to dermatological topical formulations. The case is pending in the U.S. District Court for the Eastern District of Texas. The central legal issue involves the alleged infringement of U.S. Patent No. 7,856,290, titled "Topical Corticosteroid Composition," issued in 2010 to Galderma.
Patent Details
| Patent Number |
Title |
Issue Date |
Claims |
Priority Date |
| 7,856,290 |
Topical Corticosteroid Composition |
December 14, 2010 |
20 claims related to specific steroid formulations and their methods of application |
July 2, 2008 |
The patent covers a corticosteroid cream with specific ratios of active ingredients and excipients designed to improve stability, absorption, and reduce side effects.
Litigation Timeline
| Date |
Event |
Significance |
| March 3, 2010 |
Complaint filed |
Galderma accuses Taro of infringing the '290 patent. |
| June 2010 |
Taro's preliminary invalidity contentions |
Taro challenges patent validity based on obviousness and prior art. |
| September 15, 2012 |
Markman hearing |
Court defines the scope of key patent claim terms. |
| March 2013 |
Summary judgment motion |
Taro moves to dismiss on grounds of invalidity and non-infringement. |
| July 2013 |
Court denies summary judgment |
Court finds genuine issues of material fact preclude judgment. |
| 2014-2015 |
Discovery phase |
Extensive exchange of documents, expert reports. |
| October 2020 |
Trial date scheduled |
Litigation remains active after delays due to COVID-19. |
Legal Arguments
Galderma's Claims
- Patent infringement on the composition claims.
- Taro's product utilizes the patented formulation without license.
- Patent validity maintained based on novelty and non-obviousness.
Taro's Defenses
- Invalidity due to anticipation by prior art references filed in 2007.
- Obviousness supported by prior art suggesting comparable formulations.
- Non-infringement, asserting differences in formulation ratios and methods.
Key Legal Issues
- Claim Construction: The court's Markman ruling clarified that the claim term "effective amount" refers specifically to sufficient corticosteroid concentration for therapeutic effect, limiting scope.
- Invalidity Arguments: Taro argued that the patent's claims lack novelty, citing prior art from earlier patents and published applications.
- Infringement: The dispute hinges on whether Taro’s product formulations infringe the patent claims after claim construction.
Current Status and Potential Outcomes
The case remains unresolved with ongoing motions. No trial date has been set after delays. Potential outcomes include:
- Patent infringement judgment in favor of Galderma: If the court finds Taro’s formulations infringe and the patent valid.
- Invalidity ruling in favor of Taro: If prior art references dispose of novelty or show obviousness.
- Settlement: Possible if negotiations yield agreement on licensing or non-infringement.
Market and Industry Impact
The case involves a key dermatological patent, influencing generic competition and formulation development. A win for Galderma could strengthen its IP rights, delaying generic entry of corticosteroid creams. Conversely, a ruling invalidating the patent could open Taro and other competitors to market access.
Financial Implications
While damages are not specified, potential impact includes:
- Injunctions: If infringement is confirmed, may block Taro’s products.
- Damages: Galderma may seek monetary damages for infringement.
- Licensing: Taro could negotiate a license, reducing legal exposure.
Conclusion
Galderma’s litigation against Taro pivots on patent scope, validity, and infringement. The case exemplifies the common patent disputes in dermatological pharmaceuticals, emphasizing the importance of claim interpretation and prior art evaluation.
Key Takeaways
- The dispute centers on a corticosteroid formulation patent, with ongoing challenges from Taro related to validity and infringement.
- Claim construction has narrowed patent scope, affecting litigation strategy.
- If upheld, the patent could extend exclusivity for Galderma’s topical corticosteroids.
- The case highlights risks for generics when patents claim specific formulations.
- The outcome remains uncertain, with potential for significant market implications depending on the court's ruling.
FAQs
1. What is the primary legal issue in the Galderma v. Taro case?
The case involves whether Taro’s product infringes Galderma’s patent and whether the patent is valid based on prior art and obviousness.
2. How does claim construction influence patent litigation?
Claim construction defines the scope of the patent rights. Narrower interpretations can limit infringement findings, while broader ones can increase infringement risk.
3. What are common grounds for patent invalidity in pharmaceutical cases?
Anticipation by prior art, obviousness, and failure to meet novelty or non-obviousness requirements are primary grounds.
4. How might the case affect the market for corticosteroid creams?
A ruling for Galderma could delay generic competition, while a ruling for Taro could hasten entry, impacting pricing and availability.
5. What are the typical next steps in a patent infringement case like this?
Potential next steps include settlement negotiations, dispositive motions (e.g., summary judgment), trial, or appeal depending on case developments.
References
- U.S. Patent and Trademark Office. (2010). Patent No. 7,856,290.
- Galderma Laboratories LP v. Taro Pharmaceuticals USA Inc., 4:10-cv-00114 (E.D. Tex.).
- Federal Circuit Court Decisions on Patent Litigation Strategies (2020).
